Arcellx, Inc. Arcellx, Inc.

Arcellx, Inc.

ACLX

Rangering i aksjer #2787
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Aksjekurs
$115.07
Sist synkronisert: 2026-05-15
Markedsverdi
$6.73B
Endring (1 dag)
0.00%
Endring (1 år)
34.40%
Land
US
Handel Arcellx, Inc. (ACLX)

Kategori

Healthcare
Antall utestående aksjer for Arcellx, Inc. (ACLX)
Antall utestående aksjer per December 2025: 56.31M
Ifølge Arcellx, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 56.31M. Ved slutten av December 2023 hadde selskapet 48.06M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Arcellx, Inc. (ACLX) fra 2018 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
2026 (TTM) 56.31M 5.11%
2024 53.57M 11.45%
2023 48.06M 8.97%
2022 44.11M 31.49%
2021 33.54M 54.04%
2020 21.78M -37.39%
2019 34.78M 20,905.45%
2018 165.58K 0.00%
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 350.93%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 603.31%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 750.56%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M 10.44%
NL